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Abstract
Background: Current COPD guidelines advocate a fixed < 0.70 FEV1/FVC cutpoint to define airflow obstruction.
We compared rate of lung function decline in respiratory symptomatic 40+ subjects who were ‘obstructive’ or
‘non-obstructive’ according to the fixed and/or age and gender specific lower limit of normal (LLN) FEV1/FVC
cutpoints.
Methods: We studied 3,324 respiratory symptomatic subjects referred to primary care diagnostic centres for
spirometry. The cohort was subdivided into four categories based on presence or absence of obstruction
according to the fixed and LLN FEV1/FVC cutpoints. Postbronchodilator FEV1 decline served as primary outcome to
compare subjects between the respective categories.
Results: 918 subjects were obstructive according to the fixed FEV1/FVC cutpoint; 389 (42%) of them were non-
obstructive according to the LLN cutpoint. In smokers, postbronchodilator FEV1 decline was 21 (SE 3) ml/year in
those non-obstructive according to both cutpoints, 21 (7) ml/year in those obstructive according to the fixed but
not according to the LLN cutpoint, and 50 (5) ml/year in those obstructive according to both cutpoints (p = 0.004).
Conclusion: This study showed that respiratory symptomatic 40+ smokers and non-smokers who show FEV1/FVC
values below the fixed 0.70 cutpoint but above their age/gender specific LLN value did not show accelerated FEV1
decline, in contrast with those showing FEV1/FVC values below their LLN cutpoint.
Keywords: Airflow obstruction, Chronic obstructive pulmonary disease, Diagnosis, Lung function decline, Primary
care, Spirometry
Background
Chronic obstructive pulmonary disease (COPD) is a dis-
ease that is characterized by irreversible and progressive
airflow obstruction, and is associated with high morbidity
and mortality [1]. COPD is predominantly diagnosed in
adults aged well over 40 years. In developed countries
cigarette smoking is the main risk factor [2], and acceler-
ated lung function decline is the predominant clinical and
prognostic hallmark of the disease [3]. Spirometry is
recommended to assess airflow obstruction, i.e. to estab-
lish the ratio of the forced expiratory volume in one
second (FEV1) and forced vital capacity (FVC). Next,
severity of obstruction is quantified by calculation of FEV1
as percentage of predicted value.
For subjects suspected of having the disease current
clinical COPD guidelines recommend a fixed FEV1/FVC
cutpoint < 0.70 (after administration of a bronchodilator)
to decide whether or not airflow obstruction is present
[1,4]. However, because lung function physiologically
declines with age [5], it has recently been advocated that
a correct definition of airflow obstruction should not be
based on a fixed cutpoint for all ages, but should take the
physiological decline into account [6]. One suggested
approach for this is to use lower limit of normal (LLN)
cutpoints based on the distribution of FEV1/FVC values
in an appropriate reference population, which takes
* Correspondence: t.schermer@elg.umcn.nl
1Department of Primary and Community Care, Radboud University Nijmegen
Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands
Full list of author information is available at the end of the article
Akkermans et al. BMC Pulmonary Medicine 2012, 12:12
http://www.biomedcentral.com/1471-2466/12/12
© 2012 Akkermans et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
gender and age differences between individuals into
account [7,8]. Several recent studies have shown high
rates of false-positive interpretations (especially among
elderly subjects) when the 0.70 fixed cutpoint is off-set
against an age-specific LLN cutpoint [9-14]. Because the
majority of COPD patients are diagnosed and managed
in primary care [15] and primary care doctors need to
differentiate between various underlying causes for the
respiratory symptoms a patient presents with (i.e.,
asthma, COPD, congestive heart failure, and a wide range
of other causes), it is especially important for them to
know which cutpoint is preferred when assessing the pre-
sence (or absence) of airflow obstruction. This is even
more important because in elderly patients co-morbid
conditions are often present, and misattribution of a
patient’s symptoms (e.g., dyspnoea) to COPD could lead
to inappropriate or delayed treatment.
We previously reported on the use of different criteria
to diagnose airflow obstruction in subjects who present
with respiratory symptoms in primary care [16]. To date,
little longitudinal research has been published to estab-
lish the course of clinical markers of COPD prognosis in
relation to the recommended diagnostic criteria for air-
flow obstruction [17-19]. An influential review acknowl-
edged that overestimation of airflow obstruction with the
fixed FEV1/FVC ratio becomes more problematic with
increasing age, but also stated that the incremental bene-
fits of changing the recommendation to use the fixed
0.70 cutpoint in COPD guidelines remain to be seen [20].
Recent discussions illustrate that there currently is no
consensus on this issue [21-23] and that there is a clear
need for further evidence.
The aim of the study reported in this paper was to assess
lung function decline in symptomatic middle-aged and
elderly subjects identified as ‘obstructive’ according to
either the fixed 0.70 FEV1/FVC cutpoint or an age- and
gender-specific LLN cutpoint for this ratio. We also inves-
tigated whether our findings and conclusions would
change when different sets of prediction equations are
used to calculate LLN cutpoints for FEV1/FVC.
Methods
Study setting and cohort
This cohort study was based on all available spirometry
tests from the period October 2001 to March 2010 from
three regional primary care diagnostic centres in the
Netherlands (the General Practice Laboratory Foundation
Etten-Leur/Breda (SHL), the Diagnostic Centre Eindho-
ven (DCE), and the General Practice Laboratory East
(SHO)). These diagnostic centres offer a range of diag-
nostic tests (including spirometry) and other healthcare
services to hundreds of general practitioners (GPs) in the
south-western and south-eastern parts of our country
since the mid- or late nineteen-nineties. When a patient
consults with respiratory symptoms and the GP suspects
an underlying chronic respiratory condition (e.g., COPD
or asthma), he or she can refer the patient to the diagnos-
tic centre for spirometry testing. When a chronic respira-
tory condition is diagnosed or still suspected, the
majority of patients enter the diagnostic centre’s moni-
toring service and return for reassessment every six to
twelve months.
Spirometry test results and accompanying demographic
(gender, age), anthropometric (height, weight) and medical
history information (self-reported smoking status and his-
tory, respiratory symptoms, medication) are recorded dur-
ing each visit using a standardized electronic format. Every
spirometry test is assessed by a respiratory consultant
whose interpretation of the test and - if applicable - diag-
nostic advice is sent to the GP, together with the actual
test results. Further details about the spirometry tests per-
formed in the diagnostic centres are described elsewhere
[16]. Since only routine lung function and respiratory
medical history data were used for our analyses and the
investigators had no access to the patients’ medical records
or information on patients’ identity, no written informed
consent was obtained.
Subject selection and definitions for airflow obstruction
We selected all data from Caucasian subjects aged ≥ 40
years with complete data regarding height, history of
cigarette smoking, and respiratory medication use for
whom at least three postbronchodilator spirometry tests
were available during a minimum follow-up of one year
(see Figure 1). We used postbronchodilator FEV1/FVC
values to determine whether or not airflow obstruction
was present in the study subjects. The following two defi-
nitions for airflow obstruction applied:
1) Fixed cutpoint definition: postbronchodilator FEV1/
FVC < 0.70. This is the definition for airflow obstruction
that is currently recommended in clinical COPD guide-
lines [1,24].
2) LLN cutpoint definition: postbronchodilator FEV1/
FVC below the subjects’ age-specific LLN value [25].
When the resulting standard deviation (SD) score (also
known as ‘standardized Z score’) was < -1.645, airflow
obstruction was present according to this definition.
This corresponds with the 5th percentile.
The principal prediction equations used to calculate
LLN values for FEV1/FVC were those recently published
by Swanney et al, which have been derived from an
appropriate Dutch general population cohort [6]. We
also used several other LLN equations as alternatives to
calculate age and gender specific cutpoints: European
Community for Steel and Coal (ECSC) [25], Falaschetti
et al [26], Brandli et al [27], Kuster et al [28], and Han-
kinson et al [29]. We selected these LLN equations
from an extensive list of reference equations [6] based
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Figure 1 Selection of study subjects from the initial primary care diagnostic centres’ spirometry databases. FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal. * based on Swanney prediction equations for FEV1/FVC [6] † subgroups D,
E, and F in Figure 2b ‡ subgroups A, B, and C in Figure 2b.
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on the following criteria: Caucasian race; includes age >
40 years; published in the last ten years. One additional
set of equations that was more recently published was
added to the selection post-hoc [28].
Categorization of airflow obstruction
Before further analysis we subdivided the study popula-
tion into four categories based on the presence of air-
flow obstruction at baseline as defined by the LLN and
the fixed 0.70 FEV1/FVC cutpoint definitions:
- ‘LLN-Fixed-’: absence of airflow obstruction accord-
ing to both definitions (further referred to as ‘non-
obstructed’ subjects);
- ‘LLN-Fixed+’: absence of airflow obstruction accord-
ing to the LLN definition, but presence of airflow
obstruction according to the fixed definition (further
referred to as ‘discordant’ subjects);
- ‘LLN + Fixed+’: presence of airflow obstruction
according to both definitions (further referred to as
‘obstructed’ subjects);
- ‘LLN + Fixed-’: presence of airflow obstruction
according to the LLN definition, but absence of airflow
obstruction according to the fixed definition.
Figure 2a illustrates these categories. Only two sub-
jects had obstruction according to the LLN definition
but not according to the fixed 0.70 definition (‘LLN +
Fixed-’). These subjects were excluded from further
analysis.
During the process of analysis we found that a sub-
stantial number of subjects (36% of the initial study
cohort) shifted to another category after their initial
visit. Because we considered consistency in classification
to be essential for the ‘proof of concept’ that underlies
the aim of this paper, we limited the analysis to subjects
who were consistently classified in the same category
(i.e., non-obstructed, discordant, or obstructed) through-
out their entire follow-up (’base case population’, see
Figure 1).
Outcomes and statistical analysis
The primary outcome to compare the clinical course of
the subjects in the three categories was the annual rate of
postbronchodilator FEV1 decline [30]. We analyzed pre-
bronchodilator FEV1 decline and pre- and postbroncho-
dilator FVC decline as secondary outcomes.
SAS® Proprietary Software 9.2 (SAS Institute Inc., Cary,
NC, USA) was used for all analyses. p < 0.05 was consid-
ered statistically significant. Baseline differences between
the non-obstructed, discordant, and obstructed categories
were tested with analysis of variance (Anova), Kruskal-
Wallis, and Pearson Chi-square tests. A random coeffi-
cient regression model with random intercept and random
slope was used to estimate the annual decline of post-
bronchodilator and prebronchodilator FEV1 and FVC in
baseline smokers and non-smokers separately (PROC
MIXED in SAS). Comparison of the discordant and
obstructed categories was the principal part of the ana-
lyses, but we also compared lung function decline between
discordant and non-obstructed subjects. We did not
include age and gender in the regression models. Because
of its known (but marginal) effect on FEV1 decline, use of
inhaled corticosteroids (regardless of the dose being pre-
scribed) during each subsequent visit was included in the
model as a time-dependent dichotomous (yes/no inhaled
corticosteroid use) covariate. As the proportion of subjects
who reported to have changed smoking status during fol-
low-up was small (4% of all baseline ex-smokers reported
to have taken up smoking again, 5% of all baseline smo-
kers reported to have stopped smoking) and very similar
for the respective categories, we did not include changes
in smoking status during follow-up in the respective
regression models for smokers and non-smokers. In order
to assess the sensitivity of our findings, we repeated the
base case analysis after categorization of the study subjects
using the selected alternative LLN prediction equations
[6,26-29].
Results
Study subjects
The total study population consisted of 5,215 respiratory
symptomatic subjects aged ≥ 40 years who had been
referred for spirometry by their GP and for whom com-
plete data for three measurements in at least one year
were available (Figure 1). 1,241 subjects were in different
categories based on the fixed and LLN definitions for
airflow obstruction during their baseline and final visits.
Tables 1 and 2 show baseline characteristics for these
subjects. 650 subjects were in the same category during
their baseline and final visits but had shifted between
categories during intermediate visits. Ultimately, 3,324
subjects (64%) could be included in the base case analy-
sis as they remained in the same category during all vis-
its. Table 3 shows characteristics for the base case
population and for the three defined categories.
In the base case population the non-obstructed (‘LLN-
Fixed-’) category comprised 2,406 subjects (72%), the
obstructed (’LLN + Fixed + ‘) category 529 subjects
(16%). 389 subjects (12% of all subjects and 42% of sub-
jects with obstruction according to the fixed FEV1/FVC
cutpoint) were classified as having airflow obstruction
according to the fixed but not to the LLN FEV1/FVC
cutpoint (’discordant’ or LLN-Fixed + category). Mean
number of spirometry tests per subject was 4.0 (SD 1.2)
and mean follow-up was 3.4 (SD 1.4) years, with no dif-
ferences between the categories (p = 0.592).
The non-obstructed category showed a higher propor-
tion of females (63%, p < 0.001), never smokers (36%, p <
0.001), and inhaled corticosteroid users (64%, p < 0.001).
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With a mean age of 67.0 (SD 10.1) years the subjects in
the discordant category were significantly older than
those in the non-obstructed (56.2 (SD 10.5) years) and
obstructed (60.3 (SD 10.2) years) categories (p < 0.001).
With a mean postbronchodilator FEV1 percentage pre-
dicted of 71.7% the discordant subjects were in between
Figure 2 A. Categories based on the lower limit of normal [6]) and fixed 0.70 FEV1/FVC definitions. FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; LLN: lower limit of normal Red diagonal line: LLN FEV1/FVC cutpoint (position and slope of this line will vary
depending on the reference equation used and the height and age of the subject); black horizontal line: fixed FEV1/FVC cutpoint at 0.70 LLN-
Fixed-: absence of obstruction according to both LLN and Fixed FEV1/FVC cutpoints (non-obstructed subjects) LLN-Fixed+: absence of
obstruction according to LLN cutpoint, but presence of obstruction according to fixed cutpoint (discordant subjects) LLN+Fixed+: presence of
obstruction according to both LLN and Fixed FEV1/FVC cutpoints (obstructed subjects) LLN+Fixed-: presence of obstruction according to LLN
cutpoint, but absence of obstruction according to fixed cutpoint. Only two subjects were present in this category, who were excluded from
further analysis (see Figure 1) B. Categories based on the lower limit of normal [6]and fixed 0.70 FEV1/FVC definitions, and subgroups of
subjects who showed a downward shift (A, B and C, n = 711) or an upward shift (D, E and F, n = 530) between categories over time.
Subgroups A: no obstruction at baseline visit, obstruction according to fixed FEV1/FVC cutpoint at last available visit. B: no obstruction at
baseline visit, obstruction according to both fixed and LLN FEV1/FVC cutpoints at last available visit. C: obstruction according to baseline FEV1/
FVC cutpoint at first visit, obstruction according to both fixed and LLN cutpoints at last available visit. D: obstruction according to fixed and LLN
FEV1/FVC cutpoints at baseline visit, obstruction according to fixed cutpoint at last available visit. E: obstruction according to fixed FEV1/FVC
cutpoint at baseline visit, no obstruction at last available visit. F: obstruction according to fixed and LLN FEV1/FVC cutpoints at baseline visit, no
obstruction at last available visit.
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the mean values observed in the other two categories
(Table 3). The obstructed subjects were significantly
more severe in terms of postbronchodilator FEV1 per-
centage predicted: 58.1% (p < 0.001).
In the non-obstructed category the respiratory consul-
tants could not provide a clear diagnostic advice to the GP
in 44% of subjects. Analysis of the non-obstructed subjects
in whom a diagnostic advice was given showed that 76%
of this category consisted of subjects with reversible
obstruction or (probable) asthma, and ~2% of subjects
with (probable) restriction. In the remaining 22% of non-
obstructed subjects the consultants recommended addi-
tional diagnostic testing (e.g., bronchial provocation, full
pulmonary function testing) and/or further follow-up in
order to exclude underlying chronic respiratory morbidity.
Rate of lung function decline
Figure 3 shows the adjusted estimates of the mean annual
postbronchodilator FEV1 decline (primary outcome) and
95% confidence intervals for base case population smo-
kers and non-smokers in each category. In all three cate-
gories smokers showed a more rapid FEV1 decline
compared to non-smokers. Rates of postbronchodilator
FEV1 decline differed significantly between the three
categories (p < 0.001). Table 4 shows that the smokers as
well as the non-smokers in the discordant category
showed a rate of postbronchodilator FEV1 decline which
was very similar to that in the non-obstructed category
(p = 0.973 for smokers, p = 0.624 for non-smokers), but
only about half the rate observed in the obstructed cate-
gory (p < 0.004 for smokers and p < 0.004 for non-
smokers).
With regard to the secondary outcomes, analysis of
prebronchodilator FEV1 values also indicated similarity
in terms of decline between the discordant and non-
obstructed categories (Table 4; p = 0.998 for smokers, p
= 0.301 for non-smokers), but dissimilarity between the
discordant and obstructed categories (p < 0.001 for smo-
kers and p = 0.016 for non-smokers). Prebronchodilator
FVC decline was statistically significantly different
between the three categories in smokers only (p <
0.001), with a significant difference in decline between
discordant (-5 ml/year) and obstructed (-46 ml/year)
subjects (p < 0.001). Postbronchodilator FVC decline
was not significantly differ between the respective
categories.
Table 1 Baseline characteristics of subjects who showed a downward shift in FEV1/FVC category between their
baseline and final visits
Subgroup
A (n = 390) B (n = 82) C (n = 239)
LLN-Fixed- ® LLN-Fixed+ LLN-Fixed- ® LLN + Fixed+ LLN-Fixed + ® LLN + Fixed+
Non-smokers
(n = 246)
Smokers
(n = 144)
Non-smokers
(n = 27)
Smokers
(n = 55)
Non-smokers
(n = 102)
Smokers
(n = 137)
Males, n (%) 133 (54) 65 (45) 14 (52) 16 (29) 80 (78) 79 (58)
Age, years (SD) 64.9 (11.0) 58.3 (9.3) 53.0 (10.3) 52.6 (9.1) 63.6 (9.2) 61.7 (9.0)
Baseline postbronchodilator FEV1/FVC (SD) 0.75 (0.04) 0.75 (0.04) 0.75 (0.05) 0.75 (0.05) 0.64 (0.04) 0.65 (0.04)
Baseline postbronchodilator FEV1, liters (SD) 2.33 (0.76) 2.33 (0.67) 2.28 (0.60) 2.10 (0.58) 2.22(0.68) 2.09 (0.66)
as % predicted* (SD) 78.0 (14.8) 76.8 (12.1) 72.8 (14.3) 71.6 (11.9) 68.8 (12.2) 67.6 (12.7)
See Figure 2b for further illustration of subgroups
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LNN: lower limit of normal; SD: standard deviation
* based on Swanney prediction equations [6]
Table 2 Baseline characteristics of subjects who showed an upward shift in FEV1/FVC category between their baseline
and final visits
Subgroup
D (n = 177) E (n = 64) F (n = 289)
LLN + Fixed + ® LLN-Fixed+ LLN + Fixed + ® LLN-Fixed- LLN-Fixed + ® LLN-Fixed-
Non-smokers
(n = 97)
Smokers
(n = 80)
Non-smokers
(n = 33)
Smokers
(n = 31)
Non-smokers
(n = 210)
Smokers
(n = 79)
Males, n (%) 65 (67) 44 (55) 16 (49) 8 (26) 105 (50) 42 (53)
Age, years (SD) 63.4 (10.3) 58.9 (10.0) 53.7 (11.2) 52.7 (7.7) 63.4 (9.7) 60 (10.6)
Baseline postbronchodilator FEV1/FVC (SD) 0.56 (0.06) 0.57 (0.06) 0.61 (0.06) 0.60 (0.06) 0.67(0.03) 0.67 (.02)
Baseline postbronchodilator FEV1, liters (SD) 1.86 (0.59) 1.99 (0.65) 2.08 (0.65) 1.87 (0.59) 2.26 (0.71) 2.24 (0.62)
as % predicted* (SD) 59.7 (13.2) 61.7 (14.0) 64.3 (15.4) 63.5 (14.0) 74.8. (12.2) 71.1 (11.3)
* based on Swanney prediction equations [6]
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Sensitivity analysis with alternative lower limit of normal
equations
Table 5 (for smokers) and 6 (for non-smokers) show the
estimates of the mean annual postbronchodilator FEV1
decline when the non-obstructed, discordant and
obstructed categories were based on alternative LLN equa-
tions. For all equations the overall differences in FEV1
decline between the categories were statistically significant
(p < 0.001, Tables 5 and 6). For non-obstructed and
obstructed smokers the mean values for the decline were
rather similar for the different equations (ranging from -20
to -22 ml/year and -47 to -50 ml/year, respectively; Table
5). For smokers in the discordant category the estimates
ranged from -4 ml/year (Brandli [27] equations) to -37 ml/
year (Hankinson [29] equations). Postbronchodilator FEV1
decline in discordant and obstructed smokers differed
significantly for the Brandli [27] equations (p < 0.001) and
showed tendency towards statistical significance for the
ECSC [25] (p = 0.094) and Kuster [28] (p = 0.087) equa-
tions (see Table 5).
The estimates for FEV1 decline in non-obstructed
non-smokers were identical for all alternative LLN equa-
tions (-15 ml/year; Table 6), and for obstructed non-
smokers the estimates ranged from -26 to -31 ml/year.
For non-smokers in the discordant category the esti-
mates ranged from -7 ml/year (Hankinson [29] equa-
tions) to -22 ml/year (Falaschetti [26] equations). FEV1
decline in discordant and obstructed non-smokers dif-
fered significantly for the Kuster [28] (p = 0.009) and
Brandli [27] (p = 0.036) equations, with tendency to sta-
tistical significance for the Hankinson [29] equations
(p = 0.061, see Table 6).
Table 3 Baseline characteristics for the base case study population (categories based on Swanney prediction
equations [6])
Total cohort
(n = 3,324)
Non-obstructed
(n = 2,406)
Discordant
(n = 389)
Obstructed
(n = 529)
p value
LLN*-Fixed- LLN*-Fixed+ LLN* + Fixed+
Follow-up time, years (SD) 3.4 (1.4) 3.4 (1.4) 3.2 (1.4) 3.4 (1.5) 0.592
Males, n (%) 1,500 (45) 894 (37) 245 (63) 361 (68) < 0.001
Age, mean (SD) 58.1 (11.0) 56.2 (10.5) 67.0 (10.1) 60.3 (10.2) < 0.001
40-49, n (%) 918 (28) 798 (33) 30 (8) 90 (17)
50-59, n (%) 1,003 (30) 758 (31) 66 (17) 179 (34)
60-69, n (%) 827 (25) 553 (23) 118 (30) 156 (29)
70-79, n (%) 512 (15) 277 (12) 144 (37) 91 (17)
> 80, n (%) 64 (2) 20 (1) 31 (8) 13 (3) < 0.001
Height, m 1.69 (0.1) 1.68 (0.1) 1.73 (0.1) 1.70 (0.1) < 0.001
BMI, kg/m [2] (SD) 27.5 (5.0) 28.2 (5.2) 27.0 (4.2) 25.0 (4.0) < 0.001
Smoking status, n (%)
Never 956 (29) 864 (36) 59 (15) 33 (6)
Former 1,360 (41) 964 (40) 192 (49) 204 (39)
Current 1,008 (30) 578 (24) 138 (36) 292 (55) < 0.001
Respiratory medication use, n (%)
Short-acting bronchodilators 1,436 (43) 1,061 (44) 147 (38) 228 (43) 0.066
Long-acting bronchodilators 1,174 (35) 841 (35) 144 (37) 189 (36) 0.715
Inhaled corticosteroids 1,972 (59) 1,550 (64) 185 (48) 237 (45) < 0.001
FEV1
Prebronchodilator, liters (SD) 2.28 (0.74) 2.46 (0.71) 2.02 (0.65) 1.64 (0.51) < 0.001
as % predicted* (SD) 74.6 (17.9) 81.1 (14.5) 65.3 (12.1) 51.7 (12.8) < 0.001
Postbronchodilator, liters (SD) 2.46 (0.77) 2.63 (0.74) 2.21 (0.68) 1.85 (0.56) < 0.001
as % predicted* (SD) 80.2 (17.4) 86.5 (14.1) 71.7 (12.3) 58.1 (13.2) < 0.001
FVC
Prebronchodilator, liters (SD) 3.23 (0.95) 3.22 (0.95) 3.24 (1.03) 3.26 (0.91) 0.708
Postbronchodilator, liters (SD) 3.35 (0.96) 3.30 (0.95) 3.43 (1.03) 3.53 (0.92) < 0.001
FEV1/FVC
Prebronchodilator (SD) 0.71 (0.12) 0.77 (0.07) 0.63 (0.05) 0.51 (0.08) < 0.001
Postbronchodilator (SD) 0.74 (0.12) 0.80 (0.05) 0.65 (0.03) 0.52 (0.08) < 0.001
BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LNN: lower limit of normal; SD: standard deviation
* based on Swanney prediction equations [6]
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Discussion
In this ‘proof of concept’ study we were primarily inter-
ested in the rate of lung function decline in subjects iden-
tified as obstructive by the fixed 0.70 FEV1/FVC cutpoint
but as non-obstructive by an age and gender specific
LLN cutpoint for this ratio (the discordant or ‘LLN-Fixed
+’ category). Analysis of our base case population showed
that the annual postbronchodilator FEV1 decline in dis-
cordant subjects was very similar to subjects who were
non-obstructive according to both definitions (i.e., LLN-
Fixed- category), but also that it was less than half the
rate of decline observed in subjects with FEV1/FVC
values below their age-specific LLN cutpoint (obstructed
or ‘LLN + Fixed+’ subjects). The difference in FEV1
decline between discordant and obstructed subjects was
highly statistically significant. Use of alternative FEV1/
FVC prediction equations generally showed that the
annual postbronchodilator FEV1 decline in discordant
subjects was lower compared with obstructed subjects.
However, the use of different prediction equations lead
to variable numbers of subjects in the respective cate-
gories, resulting in different estimates of FEV1 decline,
variances and levels of statistical significance. It is there-
fore important that the most appropriate prediction
equations for the study population are used to provide
unbiased estimates of FEV1 decline and correct
conclusions.
It is important to realize that the non-obstructed (LLN-
Fixed-) category did not consist of ‘healthy’ subjects in
respiratory terms, even while the respiratory consultants
could not provide clear diagnostic advice in 44% of non-
obstructed subjects. As the proportion of current and
former smokers was rather high in these subjects (~90%),
it is likely that the GPs included them in the respiratory
monitoring service because of their increased risk for
developing a chronic respiratory condition or persistence
of respiratory symptoms (in the absence of concomitant
spirometric abnormalities).
Comparison with existing literature
Several recent studies have looked at discrepancies
between fixed and LLN definitions for airflow obstruc-
tion and reported high rates of ‘false-positive’ diagnostic
interpretations when the 0.70 fixed cutpoint is used
[10-12,14,31]. False-positive interpretations may cause
erroneous diagnoses in individuals and inflate COPD
population prevalence rates [32]. Until now only few stu-
dies have looked at the course of clinical markers of
COPD prognosis or outcome in relation to criteria for
defining airflow obstruction. In a previous study from
our group we have shown that in a primary care cohort
of undiagnosed adults lung function below the normal
range and early respiratory signs predicted the develop-
ment and progression of COPD in the next five years
[33]. Garcio-Rio and colleagues recently reported that
subjects aged 40-80 who were ‘over-diagnosed’ with
COPD by the fixed 0.70 ratio experienced worse quality
of life compared to non-COPD subjects, but had similar
exercise capacity and frequency of exacerbations [34].
Mannino and colleagues reported that symptomatic sub-
jects aged ≥ 65 years who were classified as non-obstruc-
tive with a FEV1/FVC cutpoint based on LLN but as
obstructive when the 0.70 cutpoint was applied, showed
an increased risk of hospitalizations and death during a
decade or more of follow-up [17,19]. However, these sub-
jects were compared with healthy individuals without
respiratory symptoms, and therefore the findings from
this study do not actually address the issue of defining
airflow obstruction for diagnostic purposes in subjects
who seek medical attention for respiratory symptoms.
Another important difference between the Mannino [17]
study and our study is the age of the study population:
while Mannino included only elderly subjects, we fol-
lowed the lower age limit of 40 years for considering a
diagnosis of COPD [1], and therefore studied a popula-
tion in which a substantial number of subjects was
younger than 65 years. Earlier epidemiologic research
already showed that (in males) low FEV1/FVC is asso-
ciated with a higher risk of all-cause mortality, after con-
trolling for age, smoking, BMI, education, and respiratory
diseases [35].
The use of a fixed cutpoint also causes misclassification
of airflow obstruction in younger adults (i.e., aged < 45
years), as has recently been shown by Cerveri and collea-
gues [18]. In this age group the fixed 0.70 FEV1/FVC cut-
point identified less than 50% of subjects with evidence of
Figure 3 Differences* in postbronchodilator FEV1 decline for
smokers and non-smokers in the non-obstructed, discordant,
and obstructed categories† for the base case population. Bars
indicate 95% confidence intervals. FEV1: forced expiratory volume in
1 s; LLN: lower limit of normal. * adjusted for differences in inhaled
corticosteroid use between the categories. † based on Swanney [6]
prediction equations for FEV1/FVC.
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Table 4 Mean (standard error) results for the primary and the secondary outcomes in the three defined categories for current smokers and non-smokers in
the base case population
Category
Non-obstructed
(n = 2,406)
Discordant
(n = 389)
Obstructed
(n = 529)
p-value*
(LLN-Fixed-) (LLN-Fixed+) (LLN+Fixed+) Overall difference
between categories
LLN-Fixed+ versus
LLN-Fixed-
LLN-Fixed+ versus
LLN+Fixed+
ΔFEV1 postbronchodilator, ml/year (SE)
Smokers -21 (3) -21 (7) -50 (5) < 0.001 0.973 0.004
n 578 138 292
Non-smokers -15 (1) -17 (4) -36 (4) < 0.001 0.624 0.004
n 1828 251 237
ΔFEV1 prebronchodilator, ml/year (SE)
Smokers -13 (3) -13 (7) -50 (5) < 0.001 0.998 < 0.001
n 578 138 292
Non-smokers -9 (2) -14 (5) -30 (5) < 0.001 0.301 0.016
n 1828 251 237
ΔFVC postbronchodilator, ml/year (SE)
Smokers -18 (5) -17 (9) -33 (6) 0.133 0.914 0.154
n 578 138 292
Non-smokers -15 (2) -18 (6) -22 (5) 0.420 0.555 0.647
n 1828 251 237
ΔFVC prebronchodilator, ml/year (SE)
Smokers -12 (5) -5 (10) -46 (7) < 0.001 0.544 0.001
n 578 138 292
Non-smokers -7 (2) -15 (6) -16 (6) 0.226 0.230 0.929
n 1828 251 237
LNN: lower limit of normal; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; Δ: change;
* between group differences were analyzed with a random coefficient regression model with random intercept and random slope and were adjusted for differences in inhaled corticosteroid use between the
categories. Inhaled corticosteroid use was statistically significantly associated with lung function decline at p < 0.001 level in all regression models
Fixed: FEV1/FVC < 0.70; LLN based on Swanney prediction equations [6]
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Table 5 Sensitivity analysis for smokers: mean (SE) postbronchodilator FEV1 decline in ml/year in the three categories* based on alternative LLN prediction
equations for the base case population
Category*
Non-obstructed Discordant Obstructed p-value†
(LLN-Fixed-) (LLN-Fixed+) (LLN+Fixed+) Overall difference
between categories
LLN-Fixed+ versus
LLN-Fixed-
LLN-Fixed+ versus
LLN+Fixed+
Swanney [6], 2008 FEV1 decline -21 (3) -21 (7) -50 (5) < 0.001 0.973 < 0.001
n 578 138 292
ECSC [25], 1993 FEV1 decline -22 (3) -24 (15) -50 (3) < 0.001 0.870 0.094
n 578 29 452
Kuster [28], 2008 FEV1 decline -20 (3) -8 (20) -48 (3) < 0.001 0.599 0.087
n 563 14 557
Falaschetti [26], 2004 FEV1 decline -21 (3) -21 (18) -47 (3) < 0.001 0.985 0.153
n 546 24 542
Brandli [27], 2000 FEV1 decline -21 (3) -4 (11) -49 (4) < 0.001 0.026 < 0.001
n 575 60 397
Hankinson [29], 1999 FEV1 decline -21 (3) -37 (22) -48 (3) < 0.001 0.468 0.620
n 569 18 523
ECSC: European Community for Steel and Coal; FEV1: forced expiratory volume in 1 s; LLN: lower limit of normal; SD: standard deviation
* based on reference equations for LLN as indicated in first column
† between group differences were analyzed using random coefficient regression models with random intercept and random slope; adjustment for inhaled corticosteroid use
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Table 6 Sensitivity analysis for non-smokers: mean (SE) postbronchodilator FEV1 decline in ml/year in the three categories* based on alternative LLN
prediction equations for the base case population
Category*
Non-obstructed Discordant Obstructed p-value†
(LLN-Fixed-) (LLN-Fixed+) (LLN+Fixed+) Overall difference
between categories
LLN-Fixed+ versus
LLN-Fixed-
LLN-Fixed+ versus
LLN+Fixed+
Swanney [6], 2008 FEV1 decline -15 (1) -17 (4) -36 (4) < 0.001 0.624 < 0.001
n 1,828 251 237
ECSC [25], 1993 FEV1 decline -15 (1) -15 (8) -28 (3) < 0.001 0.975 0.132
n 1,831 71 426
Kuster [28], 2008 FEV1 decline -15 (1) -8 (12) -26 (3) < 0.001 0.076 0.009
n 1,814 28 532
Falaschetti [26], 2004 FEV1 decline -15 (1) -22 (8) -27 (3) < 0.001 0.376 0.521
n 1,785 71 488
Brandli [27], 2000 FEV1 decline -15 (1) -17 (6) -31 (3) < 0.001 0.746 0.036
n 1,828 125 349
Hankinson [29], 1999 FEV1 decline -15 (1) -7 (10) -26 (3) < 0.001 0.424 0.061
n 1,816 46 482
ECSC: European Community for Steel and Coal; FEV1: forced expiratory volume in 1 s; LLN: lower limit of normal; SD: standard deviation
* based on reference equations for LLN as indicated in first column
† between group differences were analyzed using random coefficient regression models with random intercept and random slope; adjustment for inhaled corticosteroid use
A
kkerm
ans
et
al.BM
C
Pulm
onary
M
edicine
2012,12:12
http://w
w
w
.biom
edcentral.com
/1471-2466/12/12
Page
11
of
14
airflow obstruction according to LLN cutpoints. These
misclassified (or ‘underdiagnosed’) subjects were more
likely to develop COPD in the following nine years, and
had higher respiratory related healthcare than subjects
without airflow obstruction according to the LLN cut-
points. Although we did not include subjects under the
age of 40 in our study, our findings logically follow from
those reported by Cerveri [18]: subjects who already have
an FEV1/FVC value below their LLN cutpoint at younger
age (which may still be above the fixed 0.70 FEV1/FVC
cutpoint) must have an accelerated lung function decline
in order to develop COPD in their next decades of life.
Our observations indicate that the accelerated decline in
subjects with below-LLN FEV1/FVC values seem to con-
tinue after the age of 40.
In their recent review, Soriano and colleagues acknowl-
edged the fact that overestimation of airflow obstruction
with the fixed FEV1/FVC ratio becomes more problematic
with increasing age, but also state that the incremental
benefits of changing the recommended fixed 0.70 cutpoint
in the COPD guidelines remain to be seen [20]. Our study
shows that the benefit of using age-specific FEV1/FVC
cutpoints (based on lower limits of normal) is the provi-
sion of better discrimination between subjects who do
show an accelerated lung function decline - the hallmark
of prognosis in patients with COPD - and those who do
not.
Strengths and limitations
One of the particular strengths of our study is the large
number of respiratory symptomatic subjects (3,324 in the
base case population) with repeated postbronchodilator
spirometry tests that could be included in our analysis.
This enabled us to subdivide our study cohort into three
categories based on the fixed and LLN definitions for air-
flow obstruction, while each category still contained a
substantial number of subjects. Because we used routine
data from primary care diagnostic centres, the subjects
included in our analysis are a truly representative sample
of the primary care patient population with a condition
that has the GP refer them. It is important to realize that
the ongoing debate about the most appropriate way to
define airflow obstruction [21,22] is especially relevant
for primary care physicians, as they are often confronted
with middle-aged and elderly subjects who present with
respiratory symptoms and who may or may not have
COPD, asthma or another (respiratory) condition. The
outcome of a spirometry test - often the only diagnostic
procedure available to assess lung function in primary
care - will direct their decision-making with regard to
diagnosis and treatment, and use of an inappropriate cut-
point will misinform their decisions.
Because the goal of our study was to compare three
clearly defined and consistent groups of subjects based
on fixed and LLN definitions for airflow obstruction, we
had to exclude those who shifted between categories
during follow-up (about one third of the total study
population) from the base case analysis. The finding
that one off spirometry does not seem to be sufficient to
rule in or out airflow obstruction in a substantial pro-
portion of primary care patients is an important one,
and suggests that GPs should not base a (COPD) diag-
nosis on a single spirometry test. On the other hand,
excluding these subjects clearly comes at the cost of less
generalizability. Therefore, our base case analysis should
be seen as a ‘proof of concept’ study regarding the pre-
sumption that when diagnosing COPD, it is more
appropriate to use age and gender specific cutpoints for
the FEV1/FVC than it is to use the ‘one size fits all’
fixed 0.70 cutpoint. A final limitation of our study is the
fact that we could not formally verify the diagnostic
labels that underlie the treatment that had been initiated
by the GP. Although we have looked at the interpreta-
tions from and diagnostic advice given by the respiratory
consultants (which has shown to be a valid approach
[34]), we did not have access to the GPs’ medical
records of the study subjects.
It is inevitable that if one takes certain individual charac-
teristics into account when classifying subjects in cate-
gories (in this case gender and age, as these two factors
determine the LLN cutpoint for each subject) the respec-
tive categories will differ on these particular characteristics
(see Table 3). Thus, adjusting our regression models for
the differences in age and gender between the categories
would not be appropriate in this case: these characteristics
cannot be considered as ‘confounders’ because they have
deliberately been used to categorize subjects.
Conclusions
We conclude that the use of the fixed 0.70 cutpoint for
the FEV1/FVC ratio to define airflow obstruction does
not seem to be an appropriate choice for primary care.
Middle-aged and elderly respiratory symptomatic smo-
kers as well as non-smokers who have values below this
fixed FEV1/FVC cutpoint but above their age and gender
specific lower limit of normal value, show about half the
rate of lung function decline as that observed in those
who are below their lower limit of normal value for the
ratio. The rate of decline in these ‘overdiagnosed’ subjects
does not differ from the decline observed in subjects
without airflow obstruction, although the result is depen-
dent on which FEV1/FVC prediction equation is used.
Perseverance in recommending the use of the fixed cut-
point in clinical COPD guidelines seems to lead to a high
rate of false-positive interpretations of obstructive air-
ways disease in middle-aged and elderly subjects in pri-
mary care, and will inflate prevalence figures for COPD
in population studies.
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